Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

MASI - Masimo Corporation Latest News | Finranks

Home

MASI

M

Masimo Corporation (MASI)

NMS – Real Time Price. Currency in USD

177.11

+0.22 (0.12%)

At close: Mar 27, 2026, 4:00 PM EDT

177.16

+0.05 (0.03%)

After-hours: Mar 27, 2026, 5:59 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition

This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition

Bridger Management sold 47,841 shares of Masimo in the fourth quarter. The move resulted in the quarter-end position value decreasing by $7.06 million.

This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement

This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement

Parkman Healthcare Partners initiated a 200,000-share stake in Masimo during the fourth quarter. The quarter-end position value rose by $26.01 million as a result.

Harbor Health Care ETF Q4 2025 Portfolio Review

Harbor Health Care ETF Q4 2025 Portfolio Review

Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly delivered strong absolute performance — driven by continued GLP-1 demand and the FDA approval of Zepbound — our underweight position in the name was a significant detractor from relative results. During the quarter, we purchased Avidity Biosciences, a clinical-stage biopharma company focused on RNA therapies for rare muscle diseases, and Abivax SA, a clinical-stage biopharma company focused on chronic inflammatory diseases.

Baron Health Care Fund Q4 2025 Recent Activity

Baron Health Care Fund Q4 2025 Recent Activity

During the quarter, Baron Health Care Fund added seven new positions and exited ten positions, bringing the number of positions in the Fund to 43. We bought shares of Arcutis Biotherapeutics, Inc., a biotechnology company that sells Zoryve cream and foam for the treatment of autoimmune dermatologic conditions. We sold Cidara Therapeutics, Inc. after the company announced it was being acquired by Merck for a substantial premium.

Bet on 5 Top-Ranked Stocks With Rising P/E

Bet on 5 Top-Ranked Stocks With Rising P/E

Tap five stocks, BJ, MCRI, CENT, SGHC and MASI, with increasing P/E ratios for an out-of-the-box approach.

Halper Sadeh LLC is Investigating Whether KW and MASI are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC is Investigating Whether KW and MASI are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Halper Sadeh LLC is Investigating Whether MASI and KW are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC is Investigating Whether MASI and KW are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Videos

No Data

There is no data to display

Press releases

Halper Sadeh LLC is Investigating Whether KW and MASI are Obtaining Fair Deals for their Shareholders

Halper Sadeh LLC is Investigating Whether KW and MASI are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Halper Sadeh LLC is Investigating Whether MASI and KW are Obtaining Fair Deals for their Shareholders

25.02.2026

Halper Sadeh LLC is Investigating Whether MASI and KW are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Masimo Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI

Masimo Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Masimo Corporation (NasdaqGS: MASI) to Danaher Corporation (NYSE: DHR). Under the terms of the proposed transaction, shareholders of Masimo will receive $180.00 in cash for each share of Masimo that they own. KSF is seeking to determine whether this consideration and the process that led to it are a.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Masimo Corporation (NASDAQ: MASI)

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Masimo Corporation (NASDAQ: MASI)

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Masimo Corporation (NASDAQ: MASI) related to its sale to Danaher Corporation.